SOLESENCE, INC. — Director's Dealing 2022

Nov 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2022-11-07

Reporting Person: JANKOWSKI JESS (Director, President, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-07	Common Stock	M	1500	$0.415	Acquired	60500	Direct
2022-11-07	Common Stock	S	1500	$2.03	Disposed	59000	Direct
2022-11-08	Common Stock	M	3000	$0.415	Acquired	62000	Direct
2022-11-08	Common Stock	S	3000	$2.27	Disposed	59000	Direct
2022-11-09	Common Stock	M	300	$0.415	Acquired	59300	Direct
2022-11-09	Common Stock	S	300	$2.16	Disposed	59000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-07	Common Stock (right to purchase)	$0.415	M	1500	Disposed	2023-02-14	Common Stock (74017)	Direct
2022-11-08	Common Stock (right to purchase)	$0.415	M	3000	Disposed	2023-02-14	Common Stock (72517)	Direct
2022-11-09	Common Stock (right to purchase)	$0.415	M	300	Disposed	2023-02-14	Common Stock (69517)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1000	Indirect
Common Stock	59000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Common Stock (right to purchase)	$0.52	2024-02-13	Common Stock (90000)	90000	Direct
Common Stock (right to purchase)	$0.44	2025-02-18	Common Stock (81000)	81000	Direct
Common Stock (right to purchase)	$0.42	2026-02-23	Common Stock (69000)	69000	Direct
Common Stock (right to purchase)	$0.68	2027-02-21	Common Stock (81000)	81000	Direct
Common Stock (right to purchase)	$0.82	2028-05-23	Common Stock (90000)	90000	Direct
Common Stock (right to purchase)	$0.51	2029-05-22	Common Stock (16500)	16500	Direct
Common Stock (right to purchase)	$0.45	2027-06-18	Common Stock (90000)	90000	Direct
Common Stock (right to purchase)	$4.17	2028-12-28	Common Stock (90000)	90000	Direct

Footnotes

F1: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.

F2: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.

F3: Subject to certain restrictions, beginning on this date, options vest in three equal installments.

F4: Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.

F5: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.